Moleculin Biotech, Inc. (MBRX)

Health Care·equity

$0.44

+4.25% today

Prices delayed about 15 minutes · cached page, can be an hour old or more

Market Census Score

20/ 100

Score level

Low

6 of 6 checks had data

How it compares with the broader market is one of its lowest-scoring factors; business numbers score is below the middle, price trend score is near the bottom of its range.

MBRX scores higher than 9% of the 1,101 tickers we compare it with (Health Care).

As of 9 October 2026, Moleculin Biotech, Inc. (MBRX) scores 20 out of 100 on the Market Census six-factor composite, which puts it at the Low score level. The score is made from six named factors: price trend, strength vs the market, company finances, insider trades, market mood and recent momentum. It records what they read on 9 October 2026, and it is not investment advice.

Updated 9 October 2026 · scores usually change about once a day

Key statistics

Market fields as reported. An em-dash means we hold no value for this ticker — most of the universe has no daily price or volume read.

Relative volume: 0.35× 30-day average
52-week range: 0.16 – 15.75
Market cap: $15.06M
Earnings date: 11 Nov 2026

Volume: 341,014
Avg. volume (30d): 984,417

Open: 0.42
Previous close: 0.42
Day's range (regular session): 0.41 – 0.46

The last trade can be an extended-hours trade, so it can sit outside the regular-session range.

Shown without a peer ranking — we hold no percentile for these yet, so there is nothing here to locate them against.

Beta: —
P/E (TTM): —
EPS (TTM): —

Score breakdown · six named factors

Price trend

Strength vs the market

Company finances

Insider trades

Market mood

Recent momentum

Each bar is one part of the score, from 0 to 100. Read what the score means.

Premium data held for MBRX

3 SEC Form 4 insider transactions in the last 90 daysPremium

Counts of rows Market Census holds for MBRX. A dash in the factor table above means that factor has no data for this ticker — it is not a locked value. Compare plans

What the score says about MBRX right now

Moleculin Biotech, Inc. (MBRX) currently scores 20/100 on the Market Census six-factor composite, at the Low score level. MBRX is +4.25% on the day and -9.20% over five sessions as of the most recent tick. Low is the lowest level. Much of MBRX's data reads poorly right now. Market Census does not tell you to short it; the level only describes the data. MBRX's strongest factor is insider trades at 50/100 — a fairly good read on insider buying and selling. Insider filings do not lean toward buying or selling right now — a plain read of public filings, not a signal to follow. The weakest factor is company finances at 0/100 — well below average company numbers. A low company-finances reading is the canonical "value trap" warning: technical setups on broken fundamentals don't tend to compound.

Generated from the six-factor breakdown above. Changes when the underlying scores do, usually about once a day. More on what the score means.

See MBRX in the scanner

This page is free to read with no account at all. Signing up takes an email and a password: a free account runs the scanner on the top 10 scored rows of any scan, keeps one saved screen, a 5-ticker watchlist, and opens 12 ticker detail pages a day. The card is what starts a 30-day Premium trial — $0 that day, then $19.99/month from day 30, cancel online any time before then — and that is what turns on every matching row instead of the first 10, alerts, the 200-ticker watchlist and recent insider buys (SEC Form 4).

Create your account →Share on X Embed this score